Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Concordia Maritime signs further time charter contract for P-MAX tanker

Concordia Maritime has signed a contract to charter out the P-MAX tanker Stena Provence. The contract is for one year, with an option for a further year, and runs frommid-September 2017. The contractual partner is one of the world’s largest oil and gas companies.The vessel has previously been used by the same customer for consecutive transportation of refined petroleum products, mainly in the Asia Pacific region. This is the second time charter contract for Concordia Maritime in recent months. A similar contract was signed with the same customer in June for the P-MAX vessel Stena Paris.

TECHNOLOGICAL BREAKTHROUGH: SUCCESSFUL METHOD FOUND FOR RECYCLING BLEND TEXTILES INTO NEW FIBERS

The four-year innovative partnership between the non-profit H&M Foundation and The Hong Kong Research Institute of Textiles and Apparel (HKRITA) finds groundbreaking solutions to recycle blend textiles into new fabrics and yarns – without any quality loss – through a hydrothermal (chemical) process. The technology will be scaled up and made available to the global fashion industry. The finding is a major breakthrough in the journey towards a closed loop for textiles.“For too long the fashion industry has not been able to properly recycle its products, since there’s no commercially viable

HYGTECH ALLIANCE GOES MEDBALTICA ON 21.-23. SEPTEMBER

Six leading Finnish companies have combined their forces and expertise to create the world's first holistic hygienic product package for public spaces. New materials and solutions developed for hygiene management can reduce hospital infections by up to 60%, which means annual savings of approximately EUR 4 billion in Europe. Our antimicrobial solutions have demonstrated remarkable reductions in bacteria in independent laboratory tests as well as significant reductions of health care associated infections in real-life hospital environments. We are fighting against diseases and

Thule unveils all-new four-wheel urban stroller and more at the Kind + Jugend trade show in Cologne, Germany, September 14–17, 2017

Thule is excited to introduce their eagerly awaited four-wheel stroller, Thule Sleek, at Kind + Jugend 2017. Along with updated versions of the award-winning Thule Urban Glide and Thule Glide strollers, the high-performing Thule Chariot multisport trailers, and the wide range of child bike seats, it will make this year’s Thule booth a must-visit.For over 25 years, Thule has dedicated themselves to making life easier for active parents to bring their kids along. On nature paths as well as on city streets. This year’s big news is the introduction of Thule Sleek, Thule’s first ever four-wheel

SimCorp A/S – Share buyback program

On 24 August 2017 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 7.5m, to be executed during the period from 24 August 2017 to 31 December 2017. The following transactions have been executed under the program:       Date                 Number of shares Average Amount (DKK)

WntResearch: As announced September 4.th new research findings show that Foxy-5 counteracts spread of prostate cancer cells

WntResearch's Chief Scientific Officer, Professor Tommy Andersson, together with his research team, and in collaboration with Professor Anders Bjartell's research group, both at Lund University, has published a scientific article in the journal PLOS ONE. The article describes how Foxy-5 inhibits spread of prostate cancer cells in a model where Foxy-5 treatment is not commenced until after a primary tumor has been established in the prostate.The study results show that administration of Foxy-5, although initiated after primary tumors have been established, strongly inhibits the spread of

Statoil enters into long-term agreement with EVRY

(Oslo, 11 September 2017) Statoil has entered into a framework agreement with EVRY for the purchase of IT consulting services for a period of five years, with options to extend by 2+2+1 years. The areas covered by the agreement include data science and analytics, artificial intelligence and machine learning, robotics, and the internet of things, in addition to more traditional service areas such as IT development, visualisation and project management.“Statoil is a very important customer for EVRY. This framework agreement marks not only a continuation but also a modernisation of our

Teknos has opened a new Technology and training center in its Rajamäki premises

Teknos has built a Technology and training center in the company’s Rajamäki facilities in Finland. The opening ceremony of the new Technology and training center was held on August 30, 2017.The center will serve Teknos’ clients and staff as training facilities and paint showroom. -  We felt that we needed a place where we can provide trainings for our partners and our own staff on using our products. The facilities also allow us to test our own products, before commercializing them, in the circumstances where they will be used, says Managing Director of Teknos Finland Arto Mannonen.

Redeye: Smart Eye - Alert leader in an awakening market

Today Redeye is initiating coverage of the eye tracking software company Smart Eye. After 18 years of research, the company today is in pole position in the automotive industry, where the German premium segment is the most important. Our base case of 76 SEK provides an attractive risk/reward in relation to the current share price. Continue reading the report by Viktor Westman at: https://goo.gl/btjHmK Start following companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking.

Teleste at IBC2017: Take advantage of new opportunities in headend application design!

At IBC2017, we will demonstrate our customers’ new, innovative headend applications powered by the Teleste Luminato headend and its application module, a ‘pc-in-a-headend’. Come visit us at the show to find out how you can take advantage of the new opportunities in headend application design. Turku, Finland – 11 September 2017 – Teleste Corporation will highlight the company’s Luminato headend platform and its high adoptability to various headend applications at IBC2017. Traditionally, you have been able to configure professional headends to adjust their operation to your requirements;

An important patent granted to Biohit Acetium® Capsule in Japan

Biohit Oyj press release 11 September 2017 at 10:30 am. Local time (EEST) Biohit Acetium® Capsule was granted in July 21, 2017 an important patent in Japan, valid until May 22, 2027 (Patent No: 6178657). The Patent is entitled: “Composition and method for binding acetaldehyde in stomach.” and it covers comprehensively all the fields of application of the Biohit Acetium® Capsule, as well as its eventual future modifications in composition, dosage and indications for use. This patented invention relates to a non-toxic composition which bind carcinogenic acetaldehyde present in the

Ericsson and KDDI to Test 5G on 4.5GHz

· Ericsson and KDDI have signed a collaborative agreement for a 5G proof of concept test in several cities across Japan · The test activities will be based on the 4.5GHz frequency band, a candidate frequency band for 5G in Japan, and will be completed by March 2018 · The scope of the trial also covers interworking between LTE and 5G using 4.5GHz and 28GHz frequency bandsEricsson (NASDAQ: ERIC) and KDDI, a leading Japanese operator, have agreed to test a 5G proof of concept on the 4.5GHz frequency band in a number of cities across Japan. The 4.5GHz frequency band is one of the

ÅF introduces a new division structure and changes in Group Management as a result of the ongoing strategy review

“ÅF will continue to grow, become more international and make greater use of the knowledge we have within the company. We are now sharpening our division structure as an initial step in this effort,” says Jonas Gustavsson, President and CEO. ÅF has approximately 10,000 employees with a unique breadth of competences combining the infrastructure, industry and energy sectors with technology and digital solutions. Together with its customers, ÅF drives development within disruptive trends such as Smart Cities, Industrial Digitalization and Future of Mobility. During the spring, ÅF

Caverion to implement telematic and other technical systems for new Teollisuuskatu tunnel in Helsinki, Finland

Caverion Corporation Investor news, September 11, 2017 at 10.00 a.m. EESTCaverion to implement telematic and other technical systems for new Teollisuuskatu tunnel in Helsinki, Finland Caverion is delivering technical systems and a telematic system for managing traffic in the new Teollisuuskatu tunnel in Central Pasila in Helsinki, Finland. The delivery is valued at approximately EUR 5.4 million and the client is the City of Helsinki.  Caverion's project execution for the tunnel, which measures approximately 430 metres in length, includes a telematic system and associated

ADDvise Group’s long term financial targets

The board of directors of ADDvise Group has adopted long term financial targets. The strategy to focus on high revenue growth based on a combination of acquisitions and organic growth remains. Profitable revenue growth combined with reduced net debt to EBITDA is an overall target. Given time dividend to ADDvise Group’s shareholders will be added. ADDvise Group’s long term financial targets is not to be mistaken for an annual forecast. The financial targets should be seen as an ambition from the board and CEO. The targets will be achieved both by acquisitions and organic growth. The

Höganästo deliver customised industrial wastewater solution to SKF Brazil

Swedish metal powder company Höganäs achieves an important milestone as Cleanit® EC is chosen as the best alternative for industrial wastewater treatment at SKF Brazil. Decisive in SKF’s choice was high level of innovation and economic competitiveness.Höganäs Brazil and local partners developed a complete solution based on the patent pending electrocoagulation technology Cleanit® EC. The customised process was designed to reduce oil, grease and suspended solids and colloids in the wastewater from the bearing plant.* SKF Brazil’s primary interest was to upgrade its existing wastewater

Brighter draws down the second tranche under the financing agreement with L1 Capital and issues additional free warrants to its shareholders.

Brighter has called upon a second Tranche of SEK 10 million in line with the terms from the financing agreement communicated on the 26thof April 2017. The transaction is carried out through a private placement of convertible notes with warrants attached. It is the second tranche out of a total of up to 8 tranches totaling SEK 100 million. It is precised that SEK 29.7 million of Notes of the first Tranche out of the SEK 30 million have been converted into equity as of today, strengthening the company’s balance sheet. This investment as part of the agreement as such, serves as a great

Episurf Medical AB will exhibit at the London Knee Meeting held in London, UK, on October 3

Episurf Medical (NASDAQ: EPIS B) will exhibit at the London Knee Meeting (recognized as one of the most important meetings in the orthopaedic calendar) held in London, UK (Queen Elizabeth II Conference Centre), on Tuesday October 3. For full program, see http://www.londonkneemeeting.co.uk/. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences). For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical

Eniro has received underwriting commitments for the cash issue and extends the acceptance period for the exchange offerings one last time

Eniro has received underwriting commitments for the cash issue amounting to SEK 275 million and extends the acceptance period for the exchange offerings one last time This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition

Episurf Medical AB will exhibit at The Individualized TKA, held in Antwerp, Belgium, on September 22

Episurf Medical (NASDAQ: EPIS B) will exhibit at The Individualized TKA (a meeting organized by the Belgian and the Dutch Knee Society) held in Antwerp, Belgium (Elzenveld), on September 22. For full program see http://www.bvot.be/images/programma-uitnodiging.pdf. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences). For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is

Nuevolution to present at three investor conferences in September 2017

Stockholm, 11 September 2017 -- Nuevolution AB (publ) (NUE.ST), a leading small-molecule drug-discovery biotech company, today announced that it will be presenting at three investor conferences in the US, Sweden and Denmark in September. First, the company will present at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference will take place on 11-12 September 2017 at the Lotte New York Palace Hotel in New York City. Henrik D. Simonsen, CFO of Nuevolution AB (publ), will provide an overview of the Company’s business during the live presentation on 12 September

Net Gaming redeems existing bond loan

Net Gaming Europe AB (publ) has decided to redeem all outstanding senior secured bonds with ISIN SE000834221 (the "Bonds").Net Gaming Europe AB (publ) has decided to redeem all outstanding Bonds. The redemption will take place on 5 October 2017 with the applicable record date on 28 September 2017. The Bonds will, in connection with the redemption, be delisted from the corporate bond list of Nasdaq First North 26 September 2017. The redemption amount will be established on the redemption date. For further information please contact:Marcus Teilman, President and CEO+356 9936 7352

BillerudKorsnäs production unit in Karlsborg expected to be back to full production during next week

During the night between September 5th and 6th, there was a fire in one of the buildings at BillerudKorsnäs’ production unit in Karlsborg and the production has been stopped since then. After analysing the impact of the fire, BillerudKorsnäs now expects Karlsborg to be back to full production during the week starting with Monday September 18th."The most important thing is that no person has been injured in the fire. We have now assessed the impact of the fire and the work with making the unit ready for start of production is ongoing at high intensity. We expect full production to be reached

New clinical study shows that Probi’s probiotics support the immune system and may delay the onset of gluten intolerance in children

A randomized, double-blind, placebo-controlled intervention trial has evaluated the effect of probiotics from Probi in children genetically predisposed for gluten intolerance (Celiac Disease). The results show that the probiotics have a suppressing effect on celiac autoimmunity and may delay the onset of the disease. Celiac disease affects up to 3% of the population and currently the introduction of a lifelong gluten-free diet is the only available treatment. Consistent study results. The randomized, double-blind, placebo controlled intervention study was performed by Dr. Daniel Agardh (

There are no items matching the current filter
There are no more items matching the current filter
Back to top